ArticleERJ open research2025
Persistent tachypnoea of infancy and neuroendocrine cell hyperplasia of infancy: from systematic review to future directions.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroendocrine hyperplasia of infancy (NEHI), also called persistent tachypnoea of infancy (PTI), is one of the most prevalent forms of childhood interstitial lung disease (chILD) and one of the few with an overall favourable prognosis. Nevertheless, there is still much to be understood about the pathophysiology of NEHI and much to be done to harmonise diagnostic work-up and management. Methods: A systematic search was conducted in PubMed, Embase, Cochrane Library, Scopus and Web of Science to identify eligible studies. Results: The results are presented in a narrative format, providing an overview of the current understanding of NEHI epidemiology, clinical presentation, investigations and outcomes. In-depth discussions include the roles of clinical assessment, chest computed tomography scan and lung biopsy, along with prospects for new diagnostic tools. Additionally, the discussion covers the pathophysiology of NEHI, focusing on the possible roles of genetic predisposition and infectious triggers. Conclusions: The morbidity of NEHI is particularly significant in the first months of life, underscoring the need for clinical and basic research to develop new targeted treatments. Some of these are discussed in this review. Finally, the improved diagnosis of this rare lung disease is facilitating the formation of new parent groups, which are becoming a crucial asset for progress.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.